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Understanding the nature of association
between anxiety phenotypes and anorexia
nervosa: a triangulation approach
E. Caitlin Lloyd1,2,3*, Hannah M. Sallis4,5,6, Bas Verplanken7, Anne M. Haase1,8,9 and Marcus R. Munafò4,5,10
Abstract
Background: Evidence from observational studies suggests an association between anxiety disorders and anorexia
nervosa (AN), but causal inference is complicated by the potential for confounding in these studies. We triangulate
evidence across a longitudinal study and a Mendelian randomization (MR) study, to evaluate whether there is
support for anxiety disorder phenotypes exerting a causal effect on AN risk.
Methods: Study One assessed longitudinal associations of childhood worry and anxiety disorders with lifetime AN
in the Avon Longitudinal Study of Parents and Children cohort. Study Two used two-sample MR to evaluate: causal
effects of worry, and genetic liability to anxiety disorders, on AN risk; causal effects of genetic liability to AN on
anxiety outcomes; and the causal influence of worry on anxiety disorder development. The independence of effects
of worry, relative to depressed affect, on AN and anxiety disorder outcomes, was explored using multivariable MR.
Analyses were completed using summary statistics from recent genome-wide association studies.
Results: Study One did not support an association between worry and subsequent AN, but there was strong
evidence for anxiety disorders predicting increased risk of AN. Study Two outcomes supported worry causally
increasing AN risk, but did not support a causal effect of anxiety disorders on AN development, or of AN on anxiety
disorders/worry. Findings also indicated that worry causally influences anxiety disorder development. Multivariable
analysis estimates suggested the influence of worry on both AN and anxiety disorders was independent of
depressed affect.
Conclusions: Overall our results provide mixed evidence regarding the causal role of anxiety exposures in AN
aetiology. The inconsistency between outcomes of Studies One and Two may be explained by limitations
surrounding worry assessment in Study One, confounding of the anxiety disorder and AN association in
observational research, and low power in MR analyses probing causal effects of genetic liability to anxiety disorders.
The evidence for worry acting as a causal risk factor for anxiety disorders and AN supports targeting worry for
prevention of both outcomes. Further research should clarify how a tendency to worry translates into AN risk, and
whether anxiety disorder pathology exerts any causal effect on AN.
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Background
Anorexia nervosa (AN) is a serious eating disorder char-
acterised by persistent restriction of caloric intake and
fear of weight gain in the context of a low body weight
[1]. The lifetime prevalence rate of AN is estimated to
be as great as 4% in women [2]. The disorder has a range
of lasting physical health complications, and one of the
highest mortality rates of all psychiatric illness [3], yet
no single treatment or set of treatments is consistently
successful [4].
Despite considerable recent research into AN, with re-
spect to a range of possible causal mechanisms (e.g.,
genetic, neural, psychological and personality factors),
the aetiology remains largely unknown. A number of
models of illness propose a causal role of anxiety that
does not surround eating and weight gain (i.e., anxiety
not explained by a diagnosis of AN) in the development
of AN. In particular, it is suggested that for those who
develop AN, dietary restriction reduces anxiety, making
restrictive eating a valuable coping mechanism, to en-
courage its continuation [5–8]. Empirical research find-
ings provide some support for such models. Anxiety
disorder prevalence is elevated in AN populations, as
compared to the general population [9, 10], and retro-
spective studies report anxiety disorder pathology to pre-
cede the onset of AN [9, 11]. The small collection of
prospective research provides mixed support for associa-
tions between specific anxiety disorder diagnoses and
AN development [12–14]. The largest and most compre-
hensive longitudinal study to date was completed using
Danish national registry data [15]. This study reported
certain anxiety disorders (generalised anxiety disorder
and social phobia) to predict increased risk of future AN
onset, but associations did not survive adjustment for all
other anxiety/stress disorders (including OCD). Presence
of any anxiety/stress disorder was robustly associated
with greater risk of subsequent AN, though effects were
stronger in men and largely driven by OCD/social pho-
bia. Outcomes potentially reflect that while specific anx-
iety disorder diagnoses generally cannot explain AN
onset beyond anxious pathology that exists across the
anxiety disorders, the latter indicates elevated risk of fu-
ture AN diagnosis. This conclusion is consistent with
those of smaller retrospective studies that have found
greater general childhood anxiety (i.e. not specific to any
given disorder) in individuals who later developed AN
(for review see [12, 16]).
Longitudinal studies in which the exposure is mea-
sured prior to the outcome are more robust to bias
resulting from reverse causation compared with cross-
sectional, and retrospective case-control, studies. How-
ever, all observational research is vulnerable to bias due
to confounding from unmeasured, or inadequately mea-
sured, factors [17]. The potential for shared causal risk
factors to explain associations between anxiety disorders
and AN means that conclusions regarding the causal ef-
fects of anxiety disorders on AN cannot be based on
findings of longitudinal studies, and the yielded temporal
associations, alone. As an example, normative concerns
of a given developmental period may interact with vul-
nerability factors to produce psychiatric pathology.
Weight concerns emerging later in the course of devel-
opment relative to other types of concerns (and in par-
ticular, those more typical of earlier childhood) could
explain AN occurring after anxiety disorders, rather than
reflecting causal effects of anxiety disorders on AN.
Triangulating, or integrating, findings across longitu-
dinal studies with those of alternative design that are
subject to different potential biases can strengthen
causal inferences [18]. As such, we aimed to compare
findings across two studies using different methods to
probe associations between anxiety and AN [19]. The
precise exposures of interest were worry and anxiety dis-
orders. Worry is defined as a negatively valenced and
uncontrollable repetitive thought process that is typically
future oriented, and intended to resolve an issue with
possible negative outcomes [20]. Worry is a transdiag-
nostic and cognitive component of anxiety disorders,
which comprise a broader collection of cognitive and
physical symptoms [21, 22].
Our first study is a longitudinal cohort study that uses
data from the Avon Longitudinal Study of Parents and
Children (ALSPAC) to determine whether worry, and
anxiety disorder presence, at age 10 predict lifetime AN
by age 24. The second study employs a two-sample
Mendelian randomization (MR) approach [17, 23] to de-
termine whether there is evidence for worry and anxiety
disorders causally influencing AN risk. Causal effects in
the reverse direction were also explored in Study Two,
to further inform the nature of association between anx-
iety and AN reported in observational studies.
MR (described comprehensively by Davies and col-
leagues [24]) uses genetic variants associated with an ex-
posure of interest (here, worry and anxiety disorders) as
instruments for examining the influence of an exposure
on an outcome (Fig. 1; [17]). MR formally assesses the
effect of genetic liability to an exposure to provide evi-
dence for causal effects that is, in principle, subject to
minimal bias by confounding (including reverse caus-
ation) that complicates interpretation of observational
research. Converging evidence for an association be-
tween anxiety and AN across Studies One and Two
would thus provide a stronger basis for causal inference.
Notably, a common genetic liability for various psychi-
atric disorders (including anxiety disorders and AN) is
supported by genome-wide association study data (e.g.
[25, 26]), as well as sibling studies (e.g. [27]), and has
been labelled the p-factor. Genetic correlations between
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anxiety disorders (and worry) and AN in particular have
also been reported [28–30]. MR is able to further our
understanding of these relationships, by informing the
mechanisms underlying established genetic associations.
Since worry has been implicated in the development
of anxiety disorders (e.g. [22, 31]), we also assess the
causal influence of worry on anxiety disorders under a
MR framework in Study Two. To assess the specificity
of effects of worry, we compare these to effects of de-
pressed affect, and use a multivariable design to assess
the independent influence of worry and depressed affect
on both anxiety disorders and AN. As a consequence,
Study Two offers the potential to highlight particular
shared causal risk factors for anxiety disorders and AN
that could confound associations in studies of observa-
tional design [32]. Outcomes also inform whether the in-
fluence of worry is specific, or reflects the operation of
negative affect more broadly.
Study one
Methods
Data sources
The Avon Longitudinal Study of Parents and Children
(ALSPAC; [33–35]) is a longitudinal population cohort
study. Initially, 14,541 mothers living in Avon, UK,
whose expected delivery dates were between 1st April
1991 to 31st December 1992 were recruited. Further eli-
gible mothers have since been recruited, and the total
sample comprises 15,247 pregnancies, 14,973 live births,
and 14,899 children alive at 1 year. The ALSPAC study
website provides details of all available data, through a
fully searchable data dictionary and variable search tool
(for more information, see: http://www.bristol.ac.uk/
alspac/researchers/our-data/). Ethics approval for the
study was obtained from the ALSPAC Ethics and Law
Committee and the Local Research Ethics Committees.
The present study includes data from all consenting partic-
ipants alive at 1 year (n= 14,882). Demographic information
for participants of the current study is shown in Table 1.
Lifetime AN at age 24 was evaluated by determining, at
four data collection waves (when participants were aged
14, 16, 18 and 24 years), whether participants met DSM-5
diagnostic criteria for AN, based on previously defined
thresholds (see Micali et al., 2015) outlined in Table 2.
Diagnoses were collapsed across the four time-points; if at
any time-point a participant met criteria for AN they were
considered an AN case, and must have not met criteria at
each time-point to be considered a healthy control (or
without AN pathology). Participants were not included if
data regarding AN diagnosis was missing at one of the
time-points and they did not meet criteria for AN other-
wise. See the Online Resource for details of AN symptom
assessment.
Anxiety exposures were assessed when children were
aged 10 using the parent-report Development and Well-
being Assessment (DAWBA; [37]), administered to
mothers. The DAWBA is a structured interview that
generates psychiatric diagnoses for children and adoles-
cents based on ICD-10 [38] and DSM-IV [39] criteria.
Worry was assessed with the question ‘Does your child
worry?’, with possible response options ‘yes’ or ‘no’, pro-
viding a binary variable used in the current investigation.
Presence of generalized anxiety disorder, separation anx-
iety disorder, social phobia, and specific phobia was
assessed. Computer algorithms assigned children to
DAWBA bands indicating the likelihood of meeting
Table 1 Characteristics of Participants in Study One
Demographic
Variable
Frequencies
N (%)
Sex
Male 7601 (51·08)
Female 7280 (48·92)
Social economic status
Manual 2808 (18·87)
Non-manual 9398 (63·15)
Missing 2676 (17·98)
Ethnicity
Non-white 609 (4·09)
White 11,468 (77·06)
Missing 2805 (18·85)
Mother Parity
Primipari 5770 (38·77)
Multipari 7154 (48·07)
Missing 1958 (13·16)
Fig. 1 Mendelian randomization analysis
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DSM-IV criteria for each anxiety disorder. Children in
the top two bands were at least 50% likely to have the anx-
iety disorder in question and assigned a diagnosis; these
diagnoses broadly align with clinician judgements [40].
From assessment of the four anxiety disorders, a binary
anxiety disorder variable was derived, indicating whether
participants met criteria for any anxiety disorder at age 10.
The tetrachoric correlation between the worry and anxiety
disorder variables was estimated as 0.45.
Plausible confounders of the association between anx-
iety exposures and AN were identified from the existing
literature, and included in statistical models. These were
sex, mother lifetime AN, and body mass index (BMI) z-
score at baseline (age 10). Symptoms and diagnoses of
both anxiety disorders and AN are elevated amongst fe-
male adolescents [41, 42], and maternal AN has been as-
sociated with child psychopathology [43, 44]. Childhood
BMI has been linked to AN, and found to predict both in-
creased and decreased risk [45, 46]; elevated BMI has also
been implicated in adolescent anxiety development (e.g.
[47]). Three strong predictors of missing data in ALSPAC,
used in previous investigations probing associations be-
tween eating disorders and other psychiatric outcomes
(e.g. [48, 49]), were also included as covariates. This was
to minimise the risk of non-random missingness, and sub-
sequent bias in the estimate of association, particularly for
analyses without imputed data. The predictors of missing-
ness were: mother age at delivery, socio-economic status
(a binary variable based on occupations of both parents),
and mother parity (a binary indicator of whether mothers
had previous viable pregnancies). Covariate values were
determined from questionnaire data, apart from the BMI
variable, which was derived from clinic-assessed height
and weight, child gender, and UK reference data [50].
Figure 2 shows the data collection process for Study One.
Statistical analysis
Statistical analyses were completed using Stata v15 [51].
Binary logistic regression models (unadjusted, and adjusted
for covariates) assessed longitudinal associations between
anxiety phenotypes and AN. Models were subsequently ad-
justed for the other anxiety exposure (i.e., anxiety disorder
presence or worry), to assess the unique variance in lifetime
AN explained by worry and anxiety disorders. Given the
ALSPAC sample includes related individuals, variance ro-
bust standard errors were calculated.
Table 2 Criteria Used to Derive Anorexia Nervosa Diagnoses at Each Wave in ALSPAC Sample
Age Weight
criteria
Child report Parent report
14 Underweight Self-reported weight/shape concern OR engaged in fasting for weight loss
or to avoid weight gain at least monthly OR engaged in excessive exercise
Presence of fear of weight gain AND fat avoidance
in the 3 months prior to assessment
16 Underweight Engaged in fasting for weight loss or to avoid weight gain at least monthly
OR engaged in excessive exercise
Presence of fear of weight gain AND fat avoidance
in the 3 months prior to assessment
18 Underweight Self-reported weight/shape concern OR engaged in fasting for weight loss
or to avoid weight gain at least monthly OR engaged in excessive exercise
N/A
24 Underweight Self-reported weight/shape concern OR engaged in fasting for weight loss
or to avoid weight gain at least monthly OR engaged in excessive exercise
N/A
Underweight at ages 14–18 was determined using gender specific norms from UK reference data, and corresponded to WHO grade 1 thinness [36]. At age 24
underweight was defined as BMI < 18.5
Fig. 2 Timeline of data collection for Study One
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In primary analyses all missing data were imputed
using a multiple imputation by chained equation (MICE)
approach, which assumes data are missing at random.
The imputation model included all analytical model vari-
ables. The models also included as auxiliary variables
those used to derive AN diagnoses at each wave, to im-
prove prediction. Additional predictors of missingness
were not included in the imputation model given analyt-
ical models incorporated three such predictors. 100
datasets were imputed.
Whilst a substantial proportion of data was im-
puted, simulation studies have demonstrated that
under these conditions data imputation is able to re-
duce bias compared to complete case approaches,
and achieves the desired gains in efficiency [52]. Fur-
ther, our imputation model produced data that was
similar to that observed, suggesting its appropriate
specification (Online Resource, Table S1). Complete
case and maximum available data analyses were
undertaken for comparison with outcomes of the
primary imputed data analyses, and we present out-
comes of all models.
Results
In unadjusted analyses, worry at age 10 was associated
with increased risk of AN by age 24, however the statis-
tical evidence provided modest support for the associ-
ation, with plausible effects (i.e. those within confidence
intervals) being both positive and negative in direction
(OR = 1.60, 95% CI: 0.93 to 2.77, p = 0.09). Furthermore,
the association was attenuated towards the null when
adjusting for potential confounders, with wide confi-
dence intervals around the estimate resulting in little
evidence for an association (OR = 1.41, 95% CI: 0.78 to
2.56, p = 0.26). When anxiety disorders were added to
the model the magnitude of association was further re-
duced (OR = 1.34, 95% CI: 0.74 to 2.45, p = 0.33).
In unadjusted analyses there was statistical evidence
for an association between anxiety disorders and AN,
both in terms of the effect estimate and the correspond-
ing confidence intervals, indicating that individuals
meeting anxiety disorder criteria at age 10 were more
likely to develop AN by age 24 (OR = 2.85, 95% CI: 1.22
to 6.63, p = 0.02). In analyses adjusted for potential con-
founders the results were consistent (OR = 3.12, 95% CI:
1.13 to 8.64, p = 0.03). Adding worry to the model also
did not alter the results substantially (OR = 2·87, 95% CI:
1.05 to 7.87, p = 0.04).
Though less precise, point estimates of associations in
complete case and maximum available data analyses
were consistent with those of imputed data analyses.
Further, confidence intervals overlapped, and the pattern
of results was similar, across all three analyses. Full re-
sults are displayed in Table 3.
Discussion
Outcomes of Study One do not support a robust associ-
ation between worry at age 10 and later AN develop-
ment. In contrast, there was evidence supporting the
presence of an anxiety disorder at age 10 predicting in-
creased risk of subsequent AN. This latter finding aligns
with outcomes of cross-sectional and retrospective re-
search [10]. The association between any anxiety dis-
order and subsequent AN development has been
reported previously [12]. The evidence for longitudinal
associations between specific anxiety disorder diagnoses
and AN development is not strong [53]. However, prior
analyses have tested whether particular anxiety disorder
diagnoses explain variation in AN onset over and above
the explanatory effects of other anxiety disorders [12,
13], when large unique predictive effects may be absent.
Alternatively, methodological limitations could have re-
duced sensitivity to detect associations in past investiga-
tions. For example, some studies (e.g. [12, 14]) did not
extend follow-up periods to encompass the entire period
in which AN onset is most common (i.e., age 15–19 [54]).
The absence of clear evidence for an association be-
tween worry and AN conflicts with findings of cross-
sectional studies reporting greater worry in AN as com-
pared to healthy controls (e.g. [55],). The finding is also
surprising given worry is a core component of anxiety
disorders [21]. Worry was measured coarsely in this
study however, and the severity of worry indicated by a
positive response could have been low or high, poten-
tially masking associations between more severe levels of
worry and AN. It is also possible that worry was less ac-
curately reported by parents as compared to other anx-
iety disorder symptoms, given its unobservable nature
[56]. Limitations with the assessment of worry may have
rendered the current investigation more sensitive to as-
sociations between anxiety disorders and AN, as com-
pared to worry and AN. Notably, whilst the banding
strategy used to assign anxiety disorder diagnoses has
previously been found to result in underestimates of dis-
order prevalence relative to clinician-assigned diagnoses,
associations between disorders and risk factors have
been preserved [40].
Findings were broadly consistent across analyses with
complete case, maximally available, and imputed, data,
supporting the reliability and validity of analysis out-
comes. Statistical adjustment for plausible confounders
minimised the risk of biased estimates. However, it is a
limitation that disordered cognition and behaviour sur-
rounding eating and weight gain at baseline was not in-
cluded as a covariate, since this information was not
captured in ALSPAC. A final limitation is the single
point in time assessment of association between worry/
anxiety disorders and AN (with AN diagnosis collapsed
across multiple time-points). Although this approach
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reduced the possibility of reverse causal effects (AN on-
set prior to age 10 being rare [57]), and avoided prob-
lems with sparse data (owing to the rarity of AN at each
measurement point), a repeated measures design would
allow for capturing more proximal effects.
Study two
Methods
Data sources
Details of the GWAS data used in the MR study are pro-
vided in Table 4. Worry and depressed affect were mea-
sured by the Eysenck Personality Questionnaire-Revised
Short Form [59] neuroticism subscale (detailed in the
Online Resource). Four items assessed worry, and four
separate items assessed depressed affect. Derivation of
the separate worry and depressed affect factors from the
neuroticism scale is empirically supported [60, 61]. The
number of ‘Yes’ responses to worry items was summed
to derive a quantitative worry phenotype, and only indi-
viduals who responded with ‘Yes’ or ‘No’ (deemed valid
responses) to all items of a given cluster were included
in the GWAS [61]. The same procedure was undertaken
to determine a quantitative score, and assess genetic as-
sociations with this score, for depressed affect. The anx-
iety disorder case-control phenotype reflects the
presence of five core anxiety disorders (generalized anx-
iety disorder, panic disorder, social phobia, agoraphobia,
specific phobia [58]). The anxiety disorder GWAS data
comprised results of a meta-analysis of genome-wide as-
sociation scans from three large cohorts. The AN
phenotype was binary, indicating a diagnosis of lifetime
AN, or eating disorder not otherwise specified AN sub-
type [28]. Participants gave informed consent for study
participation and data sharing, as described in articles
detailing original GWAS for each phenotype.
Genetic instrument selection
Genetic instruments for each exposure were identified
from relevant GWAS summary statistics (Table 4). A
significance threshold of 5 × 10− 8 was used to select in-
dependent single nucleotide polymorphisms (SNPs) ro-
bustly associated with each exposure. To ensure
independence, SNPs were clumped using a threshold of
linkage disequilibrium r2 = 0.001, and a distance of 10,
Table 3 Estimates of Multiple Logistic Regression Analyses of Lifetime AN at Age 24 on Anxiety Phenotypes
Imputed data analyses
N Variable OR [95% CI] P value
Unadjusted 14,882 Worry 1.60 [0.93, 2.77] 0.09
14,882 Anxiety disorder 2.85 [1.22, 6.63] 0.02
aAdjusted 14,882 Worry 1.41 [0.78, 2.56] 0.26
14,882 Anxiety disorder 3.12 [1.13, 8.61] 0.03
bMaximally adjusted 14,882 Worry 1.34 [0.74, 2.45] 0.33
14,882 Anxiety disorder 2.87 [1.05, 7.87] 0.04
Complete case analyses
N Variable OR [95% CI] P value
Unadjusted 1977 Worry 1.76 [0.94, 3.26] 0.08
1977 Anxiety disorder 3.62 [1.07, 12.23] 0.04
aAdjusted 1977 Worry 1.55 [0.82, 2.94] 0.18
1977 Anxiety disorder 2.97 [0.69, 12.8] 0.14
bMaximally adjusted 1977 Worry 1.49 [0.78, 2.84] 0.23
1977 Anxiety disorder 2.64 [0.61, 11.47] 0.19
Maximum available data analyses
N Variable OR [95% CI] P value
Unadjusted 2396 Worry 1.87 [1.07, 3.27] 0.03
2338 Anxiety disorder 2.8 [0.84, 9.31] 0.09
aAdjusted 2039 Worry 1.55 [0.82, 2.93] 0.18
1999 Anxiety disorder 3.00 [0.7, 12.91] 0.14
bMaximally adjusted 1977 Worry 1.49 [0.78, 2.84] 0.23
1977 Anxiety disorder 2.64 [0.61, 11.47] 0.19
aAdjusted model covariates: sex, socio-economic status, mother parity, mother AN, child body mass index z-score at baseline (age 10). b Maximally adjusted
models include all covariates and the other anxiety phenotype
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000 kb. Palindromic SNPs were replaced with proxy vari-
ants in linkage disequilibrium (r2 > 0.80) with original
variants. SNPs that were missing in the outcome GWAS
were also replaced with proxy variants, for estimation of
both SNP-exposure, and SNP-outcome associations.
Where only one or two SNPs were identified as eligible
instruments, we ran an additional sensitivity analysis
using a significance threshold of 5 × 10− 6 for instrument
identification.
Statistical analyses
MR analyses were implemented in R [62] using the Two-
SampleMR package of MR-Base [63], the gsmr package
[64], and locally downloaded GWAS data [28, 29, 58, 65].
Univariable analyses
For single SNP instruments the Wald ratio (ratio of co-
efficients) method was used to estimate the causal effect.
Our primary analysis comprised the inverse variance
weighted (IVW) analysis, in which Wald ratio estimates
across different SNPs were combined using a weighted
formula. Here, the contribution of each SNP estimate is
inversely proportionate to the variance of the SNP-
outcome association.
When there were more than two SNP instruments,
multiple sensitivity analyses were completed to deter-
mine whether inferences arising from the IVW estimate
were valid. MR assumes associations between genetic in-
struments and the outcome are fully mediated by the ex-
posure, or that there is no unbalanced horizontal
pleiotropy [66]. Five multiple instrument analyses more
robust to this assumption were completed. Weighted me-
dian and weighted mode analyses, which provide consist-
ent causal estimates when a proportion of genetic
instruments are invalid [66, 67], were conducted. General-
ized Summary-data-based Mendelian randomization
(GSMR [68]), which integrates individual SNP estimates
in a manner that accounts for variance in the SNP-
exposure, as well as the SNP-outcome, association was
completed. The HEIDI-outlier method [68] was imple-
mented to detect and remove SNPs meeting criteria for
suspected pleiotropic effects in the GSMR analysis, to pro-
vide a pleiotropy-corrected estimate of causal association.
Finally, two methods that provide an estimate of pleio-
tropic effects biasing the IVW estimate, as well as a cor-
rection for these effects, were completed. These were MR
Egger [66], and the Mendelian randomization pleiotropy
residual sum and outlier (MR-PRESSO [69]) test. A com-
prehensive overview of the MR methods implemented has
been provided elsewhere [24, 70]. Though we focus on
outcomes of the primary IVW analysis, estimates from all
sensitivity analyses are presented. The strongest inferences
may be drawn when there is convergence (in terms of the
direction/magnitude of the point estimate, and range of
plausible effects indicated by confidence intervals) across
the different methods.
Consistency across the independent SNP estimates
that are combined in the IVW analysis also provides
strong support for the validity of conclusions arising
from the latter [71]. Cochrane’s Q and I2 statistics
indexed statistical heterogeneity across estimates com-
bined in the IVW analysis. When substantial heterogen-
eity was detected, leave-one-out analyses were
completed: the IVW analysis was completed leaving out
one SNP each time, enabling detection of variants having
an undue influence on results. Rucker’s Q (Q’), which
estimates heterogeneity of SNP estimates while allowing
for pleiotropic effects (i.e., for use in MR Egger analyses
[72]), was also calculated. Comparing Cochrane’s Q with
Rucker’s Q further informs whether MR Egger or IVW
models provide a better fit to the data. A larger value of
Q compared to Q’, combined with evidence of plei-
otropy, would support the MR Egger model [72].
To ensure inferences from MR analyses were direc-
tionally accurate, where causal effects were indicated,
Steiger filtering was performed [73]. The variance in
Table 4 Characteristics of GWAS of Mendelian Randomization Analyses in Study Two
Phenotype Study Resource N genome-
wide significant
SNPsa
Total Sample size
(N case,
N control)
Population Estimated SNP
heritability
Data Source
Worry Nagel et al.
2018 [29]
UK Biobank 60 348,219 European 9.1% https://ctg.cncr.nl/software/
summary_statistics
Depressed Affect Nagel et al.,
2018 [29]
UK Biobank 60 357,957 European 8.9% https://ctg.cncr.nl/software/
summary_statistics
Anxiety Disorder Purves et al.
2019 [58]
UK Biobank,
ANGST,
iPSYCH
2 114,019
(31,977 cases,
82,114 controls)
European Not reported https://drive.google.com/drive/
folders/1fguHvz7l2G45sbMI9h_
veQun4aXNTy1v
Anorexia Nervosa Watson et al.
2019 [28]
PGC 8 72,517 (16,992
cases 55,525
controls)
European 17.0% https://www.med.unc.edu/pgc/
results-and-downloads/ed./
ANGST Anxiety Neuro Genetics STudy; PGC Psychiatric Genetics Consortium
a Independent genome-wide significant SNPs identified using LD threshold of R2 < 0.001, and distance threshold of > 10,000 kb, based on 1000 genomes
reference panel
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exposure and outcome explained by the instrument was
estimated for each SNP. Where the association between
genetic instrument and exposure is stronger than corre-
sponding associations between the same instrument and
outcome, a direction of causal effect from exposure to
outcome is supported. MR analyses were replicated using
the subsample of (filtered) variants meeting this criterion,
with consistent results from original and filtered analyses
lending support to the validity of the former.
Since estimates from analyses assessing causal effects of
genetic liability to binary anxiety disorder and AN expo-
sures do not have a clear interpretation, they were trans-
formed to the liability scale using previously derived
formula [74]. These estimates (available in the Supplemen-
tary Tables) reflect increases in the outcome per standard
deviation increase in exposure liability. The effect sizes we
would be able to detect at 80% power and with alpha set to
5% were calculated using the Shiny R application ‘Rmd’
[75], and are also presented in the Supplementary Tables.
The steps for completing MR analyses, and evaluating
outcomes, are outlined in Fig. 3.
Multivariable analyses
Multivariable analyses evaluate the influence of a given
exposure that is independent of effects of other (related)
exposures, or effects of one trait adjusted for others. The
approach allows for determining whether observed
causal effects largely operate through other traits (i.e.
pleiotropy), or reflect the influence of a less specific
phenotype. We assessed the independent effects of
genetically-predicted worry and depressed affect (re-
ported to be correlated [29]) on both anxiety disorders
and AN, using a multivariable approach.
Our analyses included independent instruments asso-
ciated with at least one of the worry and depressed affect
exposures at the 5 × 10− 8 threshold, and that were avail-
able in the outcome GWAS. There were 89 variants in
the analysis assessing causal effects on AN, and 91 in the
analysis assessing causal effects on anxiety disorders.
SNP-outcome association estimates were regressed onto
SNP-exposure association estimates for both worry and
depressed affect, at the same time, with regression
weights inversely proportionate to the variance of the
SNP-outcome association.
Multivariable MR Egger analyses [76] were completed
to determine the robustness of multivariable IVW esti-
mates, and in particular to inform whether pleiotropy
was likely to be introducing bias into the IVW estimates.
As with univariable MR Egger, the multivariable exten-
sion provides an estimate of unmeasured pleiotropy
Fig. 3 MR methods for Study Two
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(unaccounted for by inclusion of additional expo-
sures), as well as pleiotropy-corrected estimates of
causal effect. SNP estimates were oriented so that the
effect allele was the risk-increasing variant with re-
spect to the worry exposure of primary interest, as
per existing recommendations [76].
Results
Figure 4 provides estimates resulting from primary IVW
analyses, and all sensitivity analyses, for univariable and
multivariable tests. For Wald ratio estimates of instru-
mental SNPs in each univariable analysis, see the Online
Resource (Figures S2-S9).
Univariable analyses
Effects of anxiety exposures on AN
The primary IVW analysis that included 2 SNPs indi-
cated a negative effect of genetic liability to anxiety
disorders on AN risk. However, the confidence inter-
vals were wide, such that there was no strong evi-
dence to support an association. Findings from
analyses including additional independent SNPs (less
strongly associated with the exposure) were consistent
(Online Resource, Figure S1).
The IVW effect estimate and surrounding confidence
intervals provided strong evidence that worry increases
AN risk (OR = 1.79, 95% CI: 1.25 to 2.55, p = 0.001). Esti-
mates of all sensitivity analyses were directionally con-
sistent (other than that of the MR Egger estimate), and
corresponding confidence intervals overlapped with
those resulting from the IVW analysis. The precision of
estimates was such that strong statistical evidence for
the association was provided by MR-PRESSO and GSMR
analysis outcomes. For all estimates see Fig. 4a.
Effects of AN on anxiety phenotypes
A reverse direction of association, from AN to the anxiety
phenotypes, was not strongly supported (Fig. 4b). Esti-
mates of effect were close to the null, and (for effects of
genetic liability to AN on anxiety disorders) imprecise.
Effects of worry on anxiety disorders
The primary IVW analysis provided strong evidence for
worry causally increasing risk of anxiety disorder devel-
opment; the point estimate and surrounding confidence
intervals indicated large effects (OR = 5.56, 95% CI: 3.87
to 7.98, p < 0.001). This association was strongly sup-
ported by outcomes of all sensitivity analyses (in terms
of resulting point estimates and the range of plausible
values indicated by confidence intervals). All estimates
are shown in Fig. 4c.
Effects of depressed affect
There was no strong evidence for a causal influence of
depressed affect on AN development in the primary
IVW analysis, with wide confidence intervals surround-
ing the effect estimate. Outcomes of the IVW analysis
did however provide strong support for depressed affect
causally increasing risk of anxiety disorder development
(OR = 4.68, 95% CI: 3.22 to 6.81, p < 0.001), as did out-
comes of weighted median, GSMR and MR-PRESSO
tests. Confidence intervals across all sensitivity analyses
largely overlapped with each other, and those of the
IVW tests (all estimates shown in Fig. 4d and e).
Steiger tests
Steiger filtering was applied to tests of the causal influence
of worry on AN and anxiety disorders, and of the causal
influence of depressed affect on anxiety disorders. Filtered
variants comprised the majority of SNPs in the original
analysis; estimates from MR analyses including only the
filtered set of variants were consistent with those of ori-
ginal analyses (Online Resource, Figures S10-S12).
Pleiotropy tests
There was no strong evidence for bias due to horizontal
pleiotropy in the IVW estimates across the analyses. The
Egger intercept did not support pleiotropy influencing
the IVW estimate, other than for the assessment of the
causal influence of depressed affect on anxiety disorders.
In all analyses, estimates of the GSMR and MR-PRESSO
tests that detect and remove pleiotropic variants were
consistent with outcomes of IVW analyses. The MR-
PRESSO tests of distortion also did not yield strong evi-
dence for pleiotropic effects biasing inferences arising
from IVW analyses.
Whilst heterogeneity amongst SNP estimates was indi-
cated in analyses testing the causal influence of worry
and depressed affect (on both AN and anxiety disorders),
confidence intervals of each SNP estimate overlapped,
and leave-one out analyses did not indicate a dispropor-
tionate influence of any single SNP. The comparison of
Cochrane’s Q with Rucker’s Q did not support MR
Egger models providing a superior model fit relative to
IVW models in any multi-SNP analysis, aside from that
evaluating causal effects of depressed affect on anxiety
disorders. For more detail see the Supplementary Tables
and Online Resource (Figures S13-S16).
Multivariable analyses
The multivariable IVW estimate for the causal influence
of worry on risk for AN development (that is independ-
ent of effects of depressed affect) indicated a positive as-
sociation, which was estimated with precision, providing
strong evidence of an effect (OR = 2.24, 95% CI: 1.34 to
3.72, p = 0.002). In contrast, there was no strong
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evidence to support an independent effect of depressed
affect on AN. The multivariable MR Egger estimates
were directionally consistent with those of multivariable
IVW analyses, although confidence intervals were wide,
to mean there was no clear evidence for a causal effect
of worry, nor depressed affect.
The multivariable IVW point estimates and confidence
intervals provided strong evidence for large causal effects
of worry (that were independent of effects of depressed
affect) on anxiety disorders (OR = 3.34, 95% CI: 1.96 to
5.68, p < 0.001). Multivariable IVW point estimates and
confidence intervals also provided strong evidence for
causal effects of depressed affect on anxiety disorders
(OR = 2.65, 95% CI: 1.51 to 4.63, p = 0.001) that were in-
dependent of effects of worry. The multivariable MR
Egger point estimates were consistent, and were suffi-
ciently precise to provide strong statistical evidence for
independent causal effects of both worry and depressed
affect on anxiety disorders. For all estimates of multivari-
able analyses, see Fig. 4 (panels f and g).
Estimates of the intercept term in multivariable MR
Egger analyses were close to zero, suggesting an absence of
bias due to directional pleiotropy in the multivariable IVW
analyses. For further details, see the Supplementary Tables.
Discussion
Our MR investigations support a causal influence of
worry on AN development, but provide no clear evi-
dence for a causal effect of anxiety disorders on AN, nor
for any reverse causal effect from AN to anxiety pheno-
types (worry and anxiety disorders). The causal influence
of worry on anxiety disorders, as well as AN, was esti-
mated, and strong statistical support for this association
was observed. Furthermore, there was evidence that
worry explained variance in AN and anxiety disorder de-
velopment independently of another component of
negative affect (depressed affect). Such serves to further
support the causal effects indicated in univariable ana-
lyses, and suggests that the apparent influence of worry
is not simply reflective of general negative affect.
Fig. 4 Results of MR analyses of Study Two
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The validity of inferences arising from MR estimates
rests on several assumptions. We adopted methods to
minimise the potential for violating these assumptions in
our primary IVW analyses (e.g. implementing signifi-
cance/independence thresholds for instrument selec-
tion), and completed several sensitivity analyses more
robust to the pleiotropic effects that serve as the largest
threat to valid inference. Across analyses, outcomes of
sensitivity analyses produced effect estimates that were
broadly consistent with those of primary IVW analyses,
both in direction and size, lending support to conclu-
sions drawn from IVW estimates. Furthermore, the
range of plausible effect sizes indicated by estimated
confidence intervals generally overlapped across the pri-
mary and sensitivity analyses. Statistical evidence pro-
vided by the sensitivity analyses was not always as strong
as that corresponding to IVW estimates, which should
be considered when interpreting the results. Equally im-
portant to consider however is the fact that a number of
these tests (most notably MR Egger and Weighted
Mode) have considerably reduced power to detect causal
effects relative to the IVW analysis [66, 67]. Further,
across the methods that provided estimates of pleiotropy
affecting the primary IVW estimate, substantial bias was
not indicated, and methods providing a correction for
potential pleiotropy did not collectively indicate distor-
tion in the primary IVW test. Although statistical het-
erogeneity was evident amongst individual SNP
estimates in various analyses, the overlapping confidence
intervals, combined with absence of any large inconsist-
encies, further supports the validity of summary esti-
mates. Causal effects indicated in primary analyses were
also supported by outcomes of Steiger filtering, and ef-
fect estimates of analyses completed with the majority
subset of variants more strongly associated with expos-
ure relative to outcome. We do note though that the
statistical evidence tended to be weaker as compared to
analyses completed with all variants.
Importantly, the evidence in Study Two that worry,
but not anxiety disorders, may causally influence AN
outcomes is inconsistent with evidence from Study One.
This may be due to confounding of the anxiety disorder
and AN association in Study One, given that MR is
intended to protect against this. The evidence for a
causal influence of worry on AN risk in the MR investi-
gation supports the possibility that limitations in worry
measurement in Study One clouded a true association
between worry and AN. The finding that worry in-
creased risk of anxiety disorder development is consist-
ent with conclusions drawn from a prior MR
investigation [29]. It also aligns with outcomes of
randomized-controlled trials (RCTs) that have manipu-
lated worry to observe subsequent changes in anxiety
symptomatology (e.g. [22]). Collectively the findings
suggest worry may act as a shared risk factor of AN and
anxiety disorders, and a factor that could confound the
association between AN and anxiety disorders in obser-
vational studies.
Depressed affect did not show the same associations
with AN; there was little evidence for causal effects of
depressed affect on AN in univariable or multivariable
analyses. Both worry and depressed affect are subcompo-
nents of neuroticism, and the assessed factors were in
fact drawn from a broader neuroticism subscale. Neur-
oticism is proposed as a causal risk factor for multiple
psychiatric pathologies [77], and has been associated
with anxiety disorders and AN previously (e.g. [78–80]).
The findings suggest that worry is the component of
neuroticism particularly relevant for AN development,
and which may contribute to shared risk for anxiety dis-
orders and AN. This explanation is more compelling
in the context of how comparable the worry and de-
pressed affect exposures are. Worry and depressed
affect were assessed in the same population, using the
same questionnaire format. Both exposures had a
similar number of SNP instruments associated with
them, with instruments explaining a similar amount
of variance in exposure, to mean analyses were simi-
larly powered [81].
In addition to assessing, and taking measures to min-
imise, bias in effect estimates, we used the largest avail-
able GWAS for exposure and outcome in each analysis,
to enhance power. Nonetheless, analyses probing causal
effects of genetic liability to anxiety disorders and AN
were under-powered except for the detection of moder-
ate/large effects (see Supplementary Tables). This results
from there being few genetic instruments in the relevant
analyses (for overview/explanation see [24]). The small
number of variants robustly associated with anxiety dis-
order and AN phenotypes, which serve as instruments
in MR analyses, is presumably due to the relatively small
size of the respective GWAS (in particular the low num-
ber of cases). In respect of anxiety disorders, heterogen-
eity amongst cases combined in the GWAS may also
have contributed to the low number of variants associ-
ated with the phenotype. As such, the absence of evi-
dence for a causal influence of anxiety disorders or AN
should not be interpreted as the lack of causal associ-
ation. Although this does not detract from the causal ef-
fects that were observed, it does limit comparability of
causal influences between phenotypes.
General discussion
In Study One, we found that anxiety disorders present at
age 10 predict subsequent AN development, but there
was no evidence to support a similar association be-
tween worry and AN. In Study Two, we did not find evi-
dence to support the association between anxiety
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disorders and AN being causal (in either direction), but
did find evidence that worry may play a causal role in
both AN and anxiety disorder development. Study Two
also suggested that causal effects of worry on AN were
unique, in that the same associations were not observed
with respect to a depressed affect exposure. Effects of
worry on both AN and anxiety disorders appeared to
exist independently of depressed affect, rather than
reflecting the influence of negative affect more generally.
Triangulating findings across these two studies, each
with different strengths, limitations and sources of bias
(see Table 5 for an overview), allows for more robust
conclusions concerning the nature of association be-
tween anxiety exposures and AN [18, 19].
The evidence for a causal influence of worry on both
anxiety disorders and AN supports the possibility that
anxiety disorders and AN are related due to the two
sharing causal risk factors. A recent study probed associ-
ations between independent transdiagnostic anxiety dis-
order factors (measured at age 10) and lifetime AN by
age 16, in the same population cohort as that of Study
One [16]. In this earlier investigation, a quantitative
worry component (derived from a factor analysis, and
reflecting worry across multiple domains) predicted AN
development, while alternative anxiety disorder compo-
nents did not. This finding is discrepant with outcomes
of our longitudinal analysis. The discordance may be ex-
plained by different operationalisations of worry (i.e., the
tendency to worry, versus the tendency to worry about
multiple different things), and our focus on anxiety dis-
order diagnoses rather than other transdiagnostic symp-
toms. Nonetheless, outcomes of the previous study [16]
are consistent with the suggestion that worry is the
component of anxiety disorders that specifically in-
creases risk of AN, and that contributes to the anxiety
disorder and AN association. Studies failing to fully ac-
count for the influence of worry when evaluating the as-
sociation between anxiety disorders and AN may thus
obtain inflated effect size estimates that give rise to in-
valid conclusions. Our first study may have been vulner-
able to this, given the relatively crude nature of worry
assessment, which likely also limited our ability to detect
predictive effects of worry.
In terms of how worry may increase AN risk, perhaps
the focus on eating and weight, and even the neurobio-
logical effects of dietary restriction, alleviates worry sur-
rounding topics unrelated to eating and weight in
individuals who develop AN. This could encourage con-
tinued engagement in AN behavior, and would be con-
sistent with proposals that concerns not explained by
AN diagnosis are causal in disorder onset (e.g. [5–8]).
Alternatively, it is only when worry becomes directed
onto eating and weight that fears of weight gain and
severe dietary restriction, or AN pathology, manifests.
Certainly, individuals with AN have elevated worry gen-
erally, but concern is particularly heightened in relation
to eating, weight and shape [82], and this concern is
considered a maintaining factor of illness. Here, worry
comprises a process that independently contributes to
risk of both anxiety disorders and AN, as has been sug-
gested for personality and neuropsychological traits [83–
85]. There may exist a cluster of shared risk factors for
anxiety disorders and AN that includes worry, and which
potentially mediates effects of a broader underlying gen-
etic liability for psychopathology [30, 85, 86]. The speci-
ficity of the effects of worry on AN observed in this
Table 5 Assumptions of the Study Designs and Action Taken to Satisfy Them
Observational Study MR study
Assumption Action to satisfy assumption
and minimise bias
Assumption Action to satisfy assumption
and minimise bias
Absence of unmeasured
or residual confounding
Inclusion of potential
confounders in analysis
models
Absence of pleiotropic effects
that influence outcome
Use of genetic instruments associated with
exposure at genome-wide significance level;
assessment of pleiotropy in the IVW estimate;
comparison of IVW estimate with those of
sensitivity analyses more robust to pleiotropic
effects; assessment of consistency of instrument
effects
Absence of reverse
causation
Assessment of anxiety exposures
prior to most common period of
AN onset
Absence of association between
genetic instrument and confounders
of exposure-outcome association
Use of genetic instruments associated with
exposure at genome-wide significance level;
assessment of consistency of instrument
effects; use of GWAS completed in European
samples only
Missing data does not
depend on unobserved
data
Imputation of missing data;
inclusion of predictors of
missingness in imputation
and analysis models;
comparison of models with
imputed, maximum available
and complete case data
Robust association between
genetic instrument and exposure
Use of genetic instruments associated with
exposure at genome-wide significance level
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study is consistent with suggestions that while a genetic
psychopathology (or p) factor operates to increase vul-
nerability to psychiatric disorders generally, it does so
via certain traits that are shared to greater or lesser ex-
tent between diagnoses (e.g. [26]). This would account
for the high co-occurrence of certain disorders [25]. It is
also consistent with the observed genetic correlation be-
tween anxiety disorders and AN, but suggests the shared
genetic risk acts as a common vulnerability, rather than
a causal pathway from one disorder to another.
Worry has been targeted in prevention interventions
for anxiety disorders, with favourable outcomes further
supporting the thinking process as a causal risk factor
[22]. Further research, and ideally that of randomised
trial design, is required to validate our findings concern-
ing the causal influence of worry on AN development.
Existing AN prevention interventions largely do not ad-
dress non-specific cognitive processes or pathology,
tending to focus on reducing disordered eating/weight-
associated cognition and behaviour [87, 88]. Future trials
might explore whether the addition of modules that ad-
dress non-specific worry can improve outcomes of exist-
ing interventions. These studies should also seek to
elucidate the mechanisms by which a tendency to worry
influences AN.
It is recognised that conclusions concerning associa-
tions between anxiety disorders and AN drawn across
the studies have largely been made in light of the limita-
tions of Study One, or observational research, and it is
necessary to acknowledge the shortcomings of Study
Two. Given low power in the respective analyses, causal
effects between anxiety disorders and AN cannot be
ruled out on the basis of our findings, and these associa-
tions require further assessment when stronger instru-
ments become available. The existence of shared risk
factors for anxiety disorders and AN certainly does not
preclude causal effects between the two. However, it
does mean power in MR studies might be lower than
what would be expected on the basis of effect estimates
from observational research. Like observational research,
MR makes a number of assumptions. Whilst we adopted
methods to minimise the risk of violating these assump-
tions, it remains possible that they were, and that false
inferences resulted. It is important to note that although
MR minimises bias due to confounding, it is possible for
genetic instruments to be associated with confounders
of a given exposure-outcome association, which could
bias estimates of effect. Consistent findings of the obser-
vational and MR study would have provided the stron-
gest evidence for an influence of worry on AN.
Nevertheless, confidence in MR findings surrounding
the influence of worry is enhanced by alignment be-
tween MR and RCT outcomes (at least with respect to
the worry and anxiety disorder association). Finally, one
limitation that should be considered when drawing con-
clusions across the two studies is that the study popula-
tions differed in age. This could have contributed to the
discrepant results of Study One and Study Two, and
highlights the importance of exploring age-dependent ef-
fects of anxiety exposures on AN development in future
work.
Conclusions
We triangulated findings across a longitudinal cohort
study and a MR investigation to inform the nature of as-
sociation between anxiety phenotypes and AN. While re-
sults across studies were not consistent, findings from
MR analyses provided support for a causal influence of
worry on AN development, highlighting potential utility
in addressing worry for AN prevention. Outcomes also
supported worry causally influencing anxiety disorder
development, and subsequently the potential for shared
causal risk factors to inflate estimates of association be-
tween anxiety disorders and AN in observational re-
search. The evidence to support a causal influence of
anxiety disorders on AN, and of AN on anxiety out-
comes, was weak, however interpretation is complicated
by low power in the relevant MR analyses. Further ex-
ploration of causal effects between anxiety disorders and
AN is recommended, and future studies should seek to
elucidate mechanisms by which worry may translate into
risk for AN and other psychiatric outcomes.
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